Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1975 of 2529 entries
View as:

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT03280030 Org: User:
Start: 04/06/18 End: 11/14/22 Due: 11/14/23

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne

Phase: N/A Priority: Normal
NCT ID: NCT02998671 Org: User:
Start: 12/22/16 End: 08/01/18 Due: 08/01/19

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01596712 Org: User:
Start: 03/31/11 End: 08/31/12 Due: 08/31/13

This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

Phase: N/A Priority: Normal
NCT ID: NCT00531440 Org: User:
Start: 11/30/01 End: - Due: -

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Phase: N/A Priority: Normal
NCT ID: NCT01126892 Org: User:
Start: 01/31/09 End: 04/30/11 Due: 04/30/12

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01047579 Org: User:
Start: 04/30/10 End: 01/31/12 Due: 01/31/13

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05358249 Org: User:
Start: 10/24/22 End: 12/22/25 Due: 12/22/26

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Phase: N/A Priority: Normal
NCT ID: NCT04764656 Org: User:
Start: 05/10/21 End: 02/16/24 Due: 02/16/25

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Phase: N/A Priority: Normal
NCT ID: NCT05776888 Org: User:
Start: 07/10/23 End: 08/31/26 Due: 08/31/27

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00403754 Org: User:
Start: 11/30/06 End: 11/30/07 Due: 11/30/08

Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Phase: N/A Priority: Normal
NCT ID: NCT01088880 Org: User:
Start: 04/30/10 End: 08/31/11 Due: 08/31/12

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT03917472 Org: User:
Start: 07/17/19 End: 03/24/21 Due: 03/24/22

Safety and Efficacy of BFH772 in Psoriasis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00987870 Org: User:
Start: 09/30/09 End: - Due: -

Study of Efficacy and Safety of ABO809 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05036668 Org: User:
Start: 04/07/22 End: 12/27/22 Due: 12/27/23

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02900651 Org: User:
Start: 10/03/16 End: 10/09/24 Due: 10/09/25

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Phase: N/A Priority: Normal
NCT ID: NCT00154232 Org: User:
Start: 06/30/04 End: - Due: -

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Phase: N/A Priority: Normal
NCT ID: NCT05215561 Org: User:
Start: 02/14/22 End: 09/28/24 Due: 09/28/25

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02278120 Org: User:
Start: 11/20/14 End: 04/20/23 Due: 04/20/24

Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT01300416 Org: User:
Start: 07/31/10 End: 07/31/12 Due: 07/31/13

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Phase: N/A Priority: Normal
NCT ID: NCT04878432 Org: User:
Start: 03/17/22 End: 09/01/24 Due: 09/01/25

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02047656 Org: User:
Start: 08/31/13 End: 08/31/14 Due: 08/31/15

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04507919 Org: User:
Start: - End: - Due: -

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01862263 Org: User:
Start: 05/31/13 End: 07/31/15 Due: 07/31/16

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Phase: N/A Priority: Normal
NCT ID: NCT02988440 Org: User:
Start: 04/20/17 End: 02/27/20 Due: 02/27/21

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Phase: N/A Priority: Normal
NCT ID: NCT06665256 Org: User:
Start: 12/17/24 End: 07/17/30 Due: 07/17/31